General ENT News

ENT

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A newer, less expensive drug used to prevent organ rejection has been shown to be equally as effective and safe as its more expensive counterpart. In a study researchers compared the effectiveness of two drugs used to reduce the chances of rejection in kidney and pancreas transplants: alemtuzumab, a new drug that costs about $1,000 per treatment, and rabbit antithymocyte globulin, which costs about four times as much. Both drugs are used in short–term treatment to rapidly lower the immune system and thus prevent organ rejection.

   

Today in Popular Press...keeping you current

Easily led ash-tray: Adolescent smokers prone to drug abuse
EurekAlert, 12/14/09

Pathological gambling may be successfully treated with medications for substance addiction
EurekAlert, 12/11/09

How calorie-restricted diets fight obesity and extend life span
EurekAlert, 12/10/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address